Trump just ordered a tenfold surge in U.S. launch activity, yet SpaceX and its peers are selling off hard. The reason why reveals a deeper tension between policy ambition and the hardware milestone that…
A surprise capital raise sent shockwaves through the AI optics trade Monday morning, pulling down not just one stock but an entire high-flying corner of the semiconductor market that had been one of 2026's…
Scott Bessent has been sitting on a cash pile nearly the size of Switzerland's economy, and officials just confirmed it could be used in ways that would reshape long-term borrowing costs for every American…
Micron's CEO just committed $10 billion to prove memory has escaped the commodity trap forever, but the market is pricing the stock like it does not believe him yet.
Two viral numbers are shaping how investors think about quantum risk across Bitcoin and XRP, but both figures measure something far narrower than the headlines suggest, and the gap between them is not the…
Two SPDR income ETFs from the same fund family, with nearly identical price tags and the same target buyer, have gone in completely opposite directions in 2026. The reason comes down to a structural…
Marvell heads into its August 27th earnings report with a streak of beats, a massive guidance raise already on the table, and the crowd pricing in near-certain upside. What happens next could define the…
Broadcom and Marvell both reported blowout AI numbers, but they are playing completely different games inside the same semiconductor supercycle, and choosing between them means deciding which kind of risk you actually want.
TD Cowen just broke from Wall Street consensus with a striking AWS revenue call that puts its forecast far above what most analysts are willing to model, and the reasoning behind that gap reveals…
Nebius stock shed more than 21% in a single week despite blowout revenue growth, leaving investors torn between a debt-fueled collapse and a generational buying opportunity hiding in plain sight.
A top Barclays biopharma analyst says the forces that froze biotech dealmaking are breaking apart, and the pharma giants shopping for acquisitions have very specific reasons they cannot afford to stop.
KLA Corporation just reported its fifth consecutive earnings beat and raised its outlook, yet the stock sits nearly 40% below its 52-week high. Something is driving that gap, and understanding it separates a value…
Anthropic is racing toward a $2 trillion IPO on explosive revenue growth, but a fresh report from the Financial Times has exposed a crack in the business model that investors cannot afford to ignore.
A prediction market near certainty, buyout rumors from a major private equity firm, and four straight earnings beats have put Workday in a position few enterprise software stocks ever occupy heading into a quarterly…
CrowdStrike heads into its August 26 earnings report carrying momentum that has surprised Wall Street eight times in a row, and the setup heading into fiscal Q2 2027 suggests investors may want to pay…
